LGVN logo

LONGEVERON INC-A

LGVNNASDAQ
🏆 #5056 by market capEarnings Nov 3US Equity
$2.71▲ $0.07 (+2.65%)
After hours · at close
🔔
Track LGVN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.6%
7d▼ 1.8%
14d▼ 60.5%
30d▼ 59.7%
ytd▼ 46.1%
1y▼ 64.6%
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
-49.9%
Declining
📊Gross Margin
69.8%
High
💵FCF Margin
-1740.4%
Thin
⚖️P/S Ratio
7.2x
Fair
Otter Score
64
Fair

Trading Snapshot

Day Range
$2.67 – $2.76
52-Week Range
$2.30 – $12.30
Volume
$2.15B
Avg Volume
$1.93B
Shares Outstanding
3.0M
Next Earnings
Nov 30, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$287,000
P/E Ratio
-0.3
P/S Ratio
7.2x
EPS (TTM)
$-7.48
Dividend Yield
0.00%
Dilution (1yr)
+54.0%

Why Investors Own LGVN

  • ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LGVN logo

LONGEVERON INC-A

LGVN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −49.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.0%▼ −15.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$23M▲ +40.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▲ +27.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.3M▲ +54.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▼ −$14M YoY
StockOtter · stockotter.space

About LONGEVERON INC-A

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$2.78
▲ +2.5% Upside
High Target$3.47
Low Target$2.32
Based on 13 analysts

Latest News & Updates

🚀
Reuters·2h ago

LONGEVERON INC-A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift LGVN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

LONGEVERON INC-A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.